Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10486MR)

This product GTTS-WQ10486MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10486MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15265MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ9596MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8901MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ11201MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ3038MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ2347MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ5395MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ4245MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW